Evotec and Bristol Myers Squibb Expand Partnership in Molecular Glue Degraders

In a significant advancement in oncology research, Evotec has announced the expansion of its strategic partnership with Bristol Myers Squibb, originally established in 2018. This collaboration focuses on the discovery and development of molecular glue degraders, a promising new class of therapeutics. Dr. Cord Dohrmann, Chief Scientific Officer of Evotec, emphasized Bristol Myers Squibb's leadership in this innovative field, highlighting the potential of molecular glue degraders to transform treatment options. The partnership leverages Evotec's proprietary PanOmics and PanHunter platforms, along with advanced artificial intelligence and machine learning capabilities, to identify high-value therapeutic targets. The initial collaboration has proven fruitful, prompting the extension of the partnership for an additional eight years. This long-term commitment aims to build a robust pipeline of molecular glue degraders that can address various therapeutic needs. Evotec's multimodal platform integrates cutting-edge technologies and scientific expertise to facilitate the development of first-in-class and best-in-class pharmaceutical products. The company has successfully established a diverse portfolio of over 200 proprietary and co-owned research and development projects, spanning from early discovery phases to clinical trials. As Evotec continues to innovate in the field of molecular glue degraders, the company remains optimistic about its future prospects. Forward-looking statements regarding revenue expectations and research expenses reflect the confidence in the partnership's potential to yield groundbreaking therapeutic solutions. For more information, visit Evotec's website or follow them on social media platforms.